Seems like it is pretty easy to be a predictor of
Post# of 148163
CytoDyn (OTCMKTS:CYDY)‘s stock had its “buy” rating restated by research analysts at HC Wainwright in a report released on Friday, Marketbeat reports. They presently have a $3.00 price target on the biotechnology company’s stock, up from their prior price target of $1.50. HC Wainwright’s price target suggests a potential upside of 7.53% from the stock’s current price.